Nick Abbott
Stock Analyst at Wells Fargo
(0.04)
# 4,211
Out of 4,836 analysts
6
Total ratings
20%
Success rate
-36.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $11.82 | -23.86% | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $2.69 | +16,610.61% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $0.29 | +414.93% | 1 | Oct 4, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $1.56 | +925.64% | 1 | Jan 6, 2022 | |
| AFMD Affimed | Maintains: Overweight | $100 → $150 | $0.18 | +82,544.63% | 1 | Mar 24, 2021 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $11.82
Upside: -23.86%
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $450
Current: $2.69
Upside: +16,610.61%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $0.29
Upside: +414.93%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $1.56
Upside: +925.64%
Affimed
Mar 24, 2021
Maintains: Overweight
Price Target: $100 → $150
Current: $0.18
Upside: +82,544.63%